Medical/Pharmaceuticals News & Press Release Distribution

Scintimun® Commercialization Partnership with Curium Pharma

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) today announces that it has entered into an agreement with Curium Pharma for the transfer of marketing and distribution rights for Scintimun® (99m Tc-be...

2025-01-13 13:08 2286

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successful...

2025-01-13 09:05 3410

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

Funding from leading investors to accelerate R&D and international expansion to make robotic surgery solutions accessible to more HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Cornerstone Robotics (the "Company"), a leading global innovator in surgical robotics, today announced that it has successful...

2025-01-13 09:05 4892

Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery

WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)

SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Suppl...

2025-01-13 08:00 3184

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

MELBOURNE, Australia and INDIANAPOLIS, Jan. 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next...

2025-01-13 06:34 3203

Duke-NUS marks 20 years with transformative S$30m in philanthropic gifts and pledges to boost next-gen medical breakthroughs

* The legacy of Duke-NUS' founding donor, the Estate of Khoo Teck Puat, continues with a transformativeS$5.5 million gift towards research. * The HEAD Foundation steps up with a S$200,000 scholarship, underpinning Duke-NUS' commitment to developing medical expertise. SINGAPORE, Jan. 11, 2025 ...

2025-01-11 22:15 4346

Duke-NUS marks 20 years with transformative S$30m in philanthropic gifts and pledges to boost next-gen medical breakthroughs

Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).

CHENGDU, China, Jan. 11, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into an exclusive license agreement (the "License Agr...

2025-01-11 17:07 5123

Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity

* Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau * No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo * Enrollment o...

2025-01-11 01:30 3038

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...

2025-01-11 00:00 3699

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...

2025-01-10 22:00 2771

Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immuno...

2025-01-10 21:01 4757

Psylo Rebrands as Xylo, with Key Board Appointments and Breakthrough Pipeline Progress

Announces Major Milestones at the JPM Healthcare Conference SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded asXylo Bio . This transformation reflects the company's growth, sharpened focus ...

2025-01-10 21:00 1921

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma

SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Adm...

2025-01-10 17:00 6150

$JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma$

Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio

HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration agreement for the global development and commercializa...

2025-01-10 15:00 2701

SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA

SEOUL, South Korea, Jan. 10, 2025 /PRNewswire/ -- SN BioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase1b/2 clinical trial. This achievement follows the designation of SNB-101 as...

2025-01-10 14:40 2192

SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA

In 2024, Complete Genomics expanded U.S. manufacturing and technology capabilities toward a diversified, reliable supply chain for its flexible and cost-effective NGS solutions

SAN JOSE, Calif., Jan. 9, 2025 /PRNewswire/ -- In 2024, Complete Genomics, a pioneering genomic sequencing company, expanded its U.S. manufacturing footprint with augmented technology capabilities to diversify its supply chain helping it to continue reliably serving customers with flexible, cost-...

2025-01-10 01:43 2855

United Imaging Announces Major Expansion of U.S. Manufacturing Space

The additional space will more than triple the square footage of the company's current production facility and headquarters inHouston, Texas HOUSTON, Jan. 9, 2025 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has signed on for additional ...

2025-01-10 01:00 2114

Argon Medical Announces First Patient Enrollment in CLEAN-PE, a Prospective, Multicenter Study of a New Treatment for Pulmonary Embolism

PLANO, Texas, Jan. 9, 2025 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the first patient enrollment in the CLEAN-PE study. The prospective, multicenter C...

2025-01-09 23:01 2684

Goertek Unveils Next-Generation Smart Ring Reference Designs: A Leap Forward in Health Monitoring and Interactive Technology

LAS VEGAS, Jan. 9, 2025 /PRNewswire/ -- Recent technological advancements in sensing, big data, cloud computing, IoT, and AI have significantly enhanced the capabilities of wearable devices in health monitoring. Goertek's latest smart ringreference designs, showcased at CES 2025, embodies these i...

2025-01-09 23:00 2574

Hengdian Group Capital and Apeloa Pharmaceutical to participate in 2025 J.P. Morgan Healthcare Conference

HANGZHOU, China, Jan. 9, 2025 /PRNewswire/ -- Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference inSan Francisco from January 13-16, 2025. HgC CEO Gary Xu and Apeloa VP George Cai will be present a...

2025-01-09 22:00 2510